Management of Methicillin-Susceptible Staphylococcus aureus Skin and Soft Tissue Infections
Introduction to Treatment Guidelines
- The Infectious Diseases Society of America (IDSA) recommends cephalexin 500 mg orally four times daily for 7-10 days as a first-line oral agent for methicillin-susceptible Staphylococcus aureus skin and soft tissue infections in adults 1, 2, 3
Rationale for Cephalexin in MSSA Infections
- Cephalexin is explicitly recommended by IDSA guidelines as an appropriate oral agent for MSSA skin and soft tissue infections at a dose of 500 mg four times daily in adults 1, 2, 3
Alternative Oral Options for MSSA
- Dicloxacillin 500 mg four times daily is the oral agent of choice for methicillin-susceptible strains in adults according to IDSA guidelines 1, 2, 3
- Clindamycin 300-450 mg four times daily is appropriate, though bacteriostatic with potential for cross-resistance in erythromycin-resistant strains 1, 2, 3
- Trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily has bactericidal activity but poorly documented efficacy 1, 2, 3
When to Use Parenteral Therapy Instead
- Patient cannot tolerate oral intake or has severe systemic infection requiring hospitalization, in which case nafcillin or oxacillin 1-2 g every 4 hours IV is the parenteral drug of choice for MSSA 1, 3
- Cefazolin 1 g every 8 hours IV is more convenient than nafcillin with less bone marrow suppression, appropriate for penicillin-allergic patients except those with immediate hypersensitivity 1, 2, 3
Dosing and Duration Considerations
- The standard adult dose is cephalexin 500 mg orally four times daily (every 6 hours) 1, 2, 3
- Duration should be 7-10 days based on clinical response, as no differences in outcome were observed between 5 versus 10 days in randomized trials of uncomplicated cellulitis 6
- Adjust for renal function if creatinine clearance is significantly impaired 3